Cargando…
Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer
AIMS: The Medical Research Council OVO5/EORTC 55955 trial showed that patients in remission after first-line therapy for ovarian cancer did not benefit from routine measurement of CA125 during follow-up. Since the presentation of these results, we have counseled patients about the options for follow...
Autores principales: | Krell, Daniel, Said Battistino, Fran, Benafif, Sarah, Ganegoda, Lochani, Hall, Marcia, Rustin, Gordon J.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499967/ https://www.ncbi.nlm.nih.gov/pubmed/28333841 http://dx.doi.org/10.1097/IGC.0000000000000956 |
Ejemplares similares
-
Cellular Senescence in the Treatment of Ovarian Cancer
por: Wang, Zehua, et al.
Publicado: (2018) -
Risk of Ovarian Cancer Relapse Score: A Prognostic Algorithm to Predict Relapse Following Treatment for Advanced Ovarian Cancer
por: Rizzuto, Ivana, et al.
Publicado: (2015) -
Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017) -
Expression of Tissue Factor in Epithelial Ovarian Carcinoma Is Involved in the Development of Venous Thromboembolism
por: Sakurai, Manabu, et al.
Publicado: (2017) -
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer
por: Zhu, Xinxin, et al.
Publicado: (2018)